CoChat

The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer

Open access
Stine, Jessica E., Guo, Hui, Sheng, Xiugui, Han, Xiaoyun, Schointuch, Monica N., Gilliam, Timothy P., Gehrig, Paola A., Zhou, Chunxiao, Bae-Jump, Victoria L. · 2016 · Oncotarget
Cited by 92

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

// Jessica E. Stine 1, * , Hui Guo 1, 2, * , Xiugui Sheng 2 , Xiaoyun Han 1, 2 , Monica N. Schointuch 1 , Timothy P. Gilliam 1 , Paola A. Gehrig 1, 3 , Chunxiao Zhou 1, 3, # , Victoria L. Bae-Jump 1, 3, # 1 Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA 2 Department of Gynecologic Oncology, ShanDong Cancer Hospital & Institute, Jinan University, Jinan, P.R. China 3 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA * These authors have contributed equally to this work # This work was presented at the Society of Gynecologic Oncology’s Annual meeting on Women’s Cancer. Chicago, IL. March 2015 Correspondence to: Victoria L. Bae-Jump, e-mail: victoria_baejump@med.unc.edu Chunxiao Zhou, e-mail: czhou@med.unc.edu Keywords: simvastatin, ovarian cancer, HMGCR, invasion, apoptosis Received: June 19, 2015 Accepted: September 23, 2015 Published: October 16, 2015 ABSTRACT Ovarian cancer is the 5th leading cause of cancer death among women in the United States. The mevalonate pathway is thought to be a potential oncogenic pathway in the pathogenesis of ovarian cancer. Simvastatin, a 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) inhibitor, is a widely used drug for inhibiting the synthesis of cholesterol and may also have anti-tumorigenic activity. Our goal was to evaluate the effects of simvastatin on ovarian cancer cell lines, primary cultures of ovarian cancer cells and in an orthotopic ovarian cancer mouse model. Simvastatin significantly inhibited cellular proliferation, induced cell cycle G1 arrest and apoptosis, and caused cellular stress via reduction in the enzymatic activity of HMGCR and inhibition of the MAPK and mTOR pathways in ovarian cancer cells. Furthermore, simvastatin induced DNA damage and reduced cell adhesion and invasion. Simvastatin also exerted anti-proliferative effects on primary cell cultures of ovarian cancer. Treatment with simvastatin in an orthotopic mouse model reduced ovarian tumor growth, coincident with decreased Ki-67, HMGCR, phosphorylated-Akt and phosphorylated-p42/44 protein expression. Our findings demonstrate that simvastatin may have therapeutic benefit for ovarian cancer treatment and be worthy of further exploration in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.5834

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 92

Metadata

Authors
Stine, J. E., Guo, H., Sheng, X., Han, X., Schointuch, M. N., Gilliam, T. P., Gehrig, P. A., Zhou, C., & Bae-Jump, V. L.
Venue
Oncotarget
Published
2015-10-16
Volume
7
Issue
1
Pages
946-960
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2235732203
Cited by
92
References
2
FWCI
2.65
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer. https://app.cochat.ai/papers/10.18632/oncotarget.5834
The paper
Stine, J. E., Guo, H., Sheng, X., Han, X., Schointuch, M. N., Gilliam, T. P., Gehrig, P. A., Zhou, C., & Bae-Jump, V. L. (2016). The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer. Oncotarget. https://doi.org/10.18632/oncotarget.5834

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.